Sotera Health (NASDAQ:SHC) Posts Earnings Results

Sotera Health (NASDAQ:SHC) released its quarterly earnings results on Tuesday. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02, FiscalAI reports. The company had revenue of $324.89 million for the quarter, compared to the consensus estimate of $319.86 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. Sotera Health’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 EPS.

Sotera Health Trading Down 6.3%

Shares of NASDAQ:SHC opened at $16.62 on Tuesday. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 29.07 and a beta of 1.85. Sotera Health has a 1-year low of $13.09 and a 1-year high of $19.85. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. The company has a 50 day moving average price of $18.48 and a 200 day moving average price of $17.03.

Insider Activity at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the transaction, the insider owned 334,279 shares of the company’s stock, valued at approximately $6,297,816.36. This represents a 30.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman directly owned 3,969,393 shares in the company, valued at $73,433,770.50. This represents a 17.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,294,515 shares of company stock worth $23,999,528. 15.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SHC has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 25th. Piper Sandler reissued an “overweight” rating and set a $25.00 target price on shares of Sotera Health in a report on Tuesday, September 8th. Weiss Ratings downgraded Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. lowered Sotera Health from a “neutral” rating to an “underweight” rating and set a $17.00 price target for the company. in a research note on Wednesday, October 14th. Finally, Barclays lifted their price target on Sotera Health from $19.00 to $22.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.38.

Sotera Health Company Profile

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.